Stem cell transplant timing for multiple myeloma with no cancer cells left
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma (a type of blood cancer).
- You are between 18 and 70 years old.
- After 4 to 6 rounds of initial treatment, tests show no cancer cells left (MRD-negative) and you have at least a very good partial response.
- You are generally healthy enough to take care of yourself (ECOG score 0 to 2).
- Your liver, kidney, and heart function are within safe limits (your doctor will check).
- You do not have certain high-risk genetic changes in your myeloma cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
This Phase 2 study tests whether people with newly diagnosed multiple myeloma can safely delay or avoid an immediate stem cell transplant if they respond well to early treatment. It aims to see if this “response-adapted” approach can still control the disease while reducing the need for upfront transplant for some patients.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.